Scarica l'app Stockscreener
33.69
1.02%
0.34
Dopo l'orario di chiusura:
33.80
0.11
+0.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$33.35
Aprire:
$33.29
Volume 24 ore:
8.09M
Relative Volume:
1.53
Capitalizzazione di mercato:
$68.28B
Reddito:
$39.71B
Utile/perdita netta:
$3.17B
Rapporto P/E:
9.7871
EPS:
3.4423
Flusso di cassa netto:
$6.05B
1 W Prestazione:
-7.32%
1M Prestazione:
-12.61%
6M Prestazione:
-25.10%
1 anno Prestazione:
-4.29%
Intervallo 1D:
$33.25
$33.79
Intervallo di 1 settimana:
$32.83
$35.63
Portata 52W:
$32.83
$45.92
Gsk Plc Adr Stock (GSK) Company Profile
Nome
Gsk Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GSK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| GSK | 33.69 | 68.28B | 39.71B | 3.17B | 6.05B | 3.4423 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-08 | Downgrade | UBS | Buy → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-03-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2024-01-03 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-03-17 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Ripresa | Goldman | Buy |
| 2023-01-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Downgrade | UBS | Neutral → Sell |
| 2022-09-15 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Ripresa | Citigroup | Neutral |
| 2022-02-11 | Downgrade | DZ Bank | Buy → Hold |
| 2021-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Hold |
| 2020-11-02 | Aggiornamento | Liberum | Hold → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-02-12 | Downgrade | Shore Capital | Hold → Sell |
| 2020-01-16 | Downgrade | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Iniziato | SVB Leerink | Outperform |
| 2019-11-21 | Aggiornamento | UBS | Neutral → Buy |
| 2019-10-11 | Aggiornamento | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Ripresa | Citigroup | Neutral |
| 2019-09-03 | Aggiornamento | Societe Generale | Sell → Buy |
| 2019-08-13 | Ripresa | JP Morgan | Neutral |
| 2019-06-17 | Ripresa | Morgan Stanley | Underweight |
| 2019-03-08 | Downgrade | Shore Capital | Buy → Hold |
| 2019-02-22 | Downgrade | UBS | Buy → Neutral |
| 2019-01-14 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-08-30 | Downgrade | Liberum | Buy → Hold |
| 2018-04-04 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Aggiornamento | Kepler | Reduce → Hold |
Mostra tutto
Gsk Plc Adr Borsa (GSK) Ultime notizie
5 Stocks to Buy While They’re Still Cheap After Earnings - Morningstar
Diabetes Care Nutrition Market Report 2024 with Forecasts to 2029 - GlobeNewswire Inc.
The 10 Best Companies to Invest in Now - Morningstar
Timor-Leste eliminates lymphatic filariasis as a public health problem - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
The Best Defensive Stocks to Buy - Morningstar
GSK Plc ADR (NYSE: GSK) Has Outstanding Potential - Stocks Register
GSK (GSK) Q3 Earnings Surpass Estimates - Yahoo Finance
What Do Analysts Think About ICICI Bank Ltd. ADR’s (NYSE:IBN) Future? - Stocks Register
GSK Plc ADR (GSK): An Important Analyst Insights - Stocks Register
5 Stocks to Buy if You’re Concerned About US Market Valuations - Morningstar
21 Best Healthcare Companies to Invest In - Morningstar
Current share price is - GSK
D-Wave Quantum Inc (QBTS) rating initates by B. Riley Securities - Knox Daily
GSK's Studies On Depemokimab For Nasal Polyps Meet Primary Goals - Barchart
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
GSK Plc ADR [GSK] is 5.59% higher this YTD. Is it still time to buy? - The DBT News
What You Didn’t Know About General Motors Company (NYSE: GM) This Week - Stocks Register
GSK’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Before You Invest, Make Sure You Check This ADT Inc (NYSE: ADT) Analysis - Stocks Register
What Are You Thinking About Investing In Medical Properties Trust Inc (NYSE: MPW) Stock? - Stocks Register
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday - sharewise
Introducing Our Rant Against GSK Plc ADR - US Post News
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy - Zacks Investment Research
Balance Sheet Insights: GSK Plc ADR (GSK)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Pilgrim’s Pride Corp. (PPC) receives an Equal-weight rating from Stephens - Knox Daily
Berenberg upgrades Carnival plc ADR (CUK) stock to a Hold - Knox Daily
JP Morgan analysts downgrades an Underweight rating for Organon & Co. (OGN) - Knox Daily
GSK Plc ADR (GSK) gets rating Downgrade from UBS - Knox Daily
GSK Plc ADR (GSK) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
Precidian to List First ADRhedged Securities in the U.S. on Cboe, Providing Exposure to Individual International Companies with an Embedded Currency Hedge - PR Newswire
Tenet Healthcare Corp. [THC] stock for 1,879,734 USD was sold by Ramsey R. Scott - Knox Daily
Ratio Analysis: Unpacking GSK Plc ADR (GSK)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GSK Plc ADR [GSK] Insider Activity: An Update for Investors - Knox Daily
GSK Plc ADR (GSK) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Cantor Fitzgerald’s latest rating for AMGN stock - Knox Daily
Nutanix Inc [NTNX] Chief Financial Officer makes an insider sale of 24,316 shares worth 1,430,939. - Knox Daily
GSK’s Stock Market Adventure: 9.44% YTD Growth Amidst Volatility - The InvestChronicle
GSK Shares Experience Decline in Value - Knox Daily
The Best Healthcare Stocks to Buy - Morningstar
Ratio Revelations: GSK Plc ADR (GSK)’s Financial Metrics in the Spotlight - The Dwinnex
Gsk Plc Adr Azioni (GSK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.03%
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):